SENZA.ST
SenzaGen AB
Price:  
5.58 
SEK
Volume:  
425.00
Sweden | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

SENZA.ST WACC - Weighted Average Cost of Capital

The WACC of SenzaGen AB (SENZA.ST) is 5.8%.

The Cost of Equity of SenzaGen AB (SENZA.ST) is 5.75%.
The Cost of Debt of SenzaGen AB (SENZA.ST) is 7.00%.

Range Selected
Cost of equity 4.90% - 6.60% 5.75%
Tax rate 0.10% - 0.30% 0.20%
Cost of debt 7.00% - 7.00% 7.00%
WACC 5.0% - 6.6% 5.8%
WACC

SENZA.ST WACC calculation

Category Low High
Long-term bond rate 2.5% 3.0%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.38 0.42
Additional risk adjustments 0.5% 1.0%
Cost of equity 4.90% 6.60%
Tax rate 0.10% 0.30%
Debt/Equity ratio 0.01 0.01
Cost of debt 7.00% 7.00%
After-tax WACC 5.0% 6.6%
Selected WACC 5.8%

SENZA.ST's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for SENZA.ST:

cost_of_equity (5.75%) = risk_free_rate (2.75%) + equity_risk_premium (5.60%) * adjusted_beta (0.38) + risk_adjustments (0.75%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.